Research Context
Our Semaglutide 10mg vial — known in community terminology as SEMA10 — is a long-acting GLP-1 receptor agonist synthesized to >99% HPLC purity for incretin and metabolic research models.
SEMA-class research compounds are widely cataloged among research peptides studied for satiety pathways, insulin signaling, and glucose homeostasis. Investigators frequently pair these compounds with adjacent GLP-1 / GIP research peptides for receptor-comparison studies.
A long-acting GLP-1 receptor agonist widely studied in metabolic and incretin research.
99% HPLC Purity · For Laboratory Research Use Only
Key Research Findings (At a Glance)
| Parameter | Summary |
|---|---|
| Peptide Structure | 31 amino acids (modified GLP-1 analog with C18 fatty acid) |
| Origin | Synthetic GLP-1 receptor agonist (94% homology to native GLP-1) |
| Primary Mechanism | Appetite suppression + glycemic control (single-pathway) |
| Key Research Areas | Obesity, Type 2 Diabetes (T2DM), cardiovascular risk, energy balance |
| Distinguishing Feature | Extended half-life (~1 week) via albumin binding and DPP-4 resistance |
| Key Differentiator from Dual/Triple Agonists | Foundational GLP-1 baseline; most extensively studied incretin |
| Common Research Vials | 5mg, 10mg, 15mg, 20mg (often searched as Sema5, Sema10, Sema15, Sema20) |
| Typical Administration | Subcutaneous injection (weekly) |
| Intended Use | Laboratory research only – not for human or veterinary consumption |
Overview
Semaglutide is a novel, long-acting synthetic peptide engineered as a highly selective glucagon-like peptide-1 (GLP-1) receptor agonist. It shares 94% structural homology with native human GLP-1 but incorporates two critical modifications: an amino acid substitution at position 8 (alanine replaced by alpha-aminoisobutyric acid, or Aib8) and a C18 fatty diacid side chain attached via a spacer at position 26. Frequently abbreviated in laboratory shorthand as Sema, or by specific vial sizes like Sema5, Sema10, Sema15, and Sema20, this compound has completed extensive Phase 3 clinical trials (the SUSTAIN and STEP programs) and is FDA-approved for type 2 diabetes (as Ozempic) and obesity (as Wegovy).
The Aib8 substitution prevents degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), while the C18 fatty acid chain allows Semaglutide to reversibly bind to circulating albumin in the blood. This albumin binding acts as a reservoir, protecting the peptide from rapid renal clearance and extending its half-life to approximately one week, enabling once-weekly dosing protocols. As the most extensively characterized GLP-1 receptor agonist, Semaglutide serves as a reference standard and control group baseline in comparative incretin research protocols.
Laboratories looking to buy research-grade Semaglutide typically evaluate these albumin-binding kinetics and GLP-1 receptor agonism endpoints under controlled study designs.
As the foundational single-pathway GLP-1 agonist, Semaglutide represents the baseline of the modern incretin therapeutic class. While it produces highly significant weight loss and glycemic control, it lacks the dual incretin (GIP) or triple agonist (glucagon) mechanisms found in newer compounds like Tirzepatide or Retatrutide.
This makes Semaglutide the critical comparator in metabolic research and the starting point for understanding incretin-based therapies.
Research-grade Semaglutide for sale is supplied as a lyophilized powder for laboratory study only.
Mechanism of Action: GLP-1 Agonism and Half-Life Extension
GLP-1 Receptor Agonism (Appetite and Glycemic Control)
Activation of GLP-1 receptors stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release, delays gastric emptying, and promotes satiety signaling in the hypothalamus. These effects drive a significant reduction in caloric intake and improve glycemic control without increasing the risk of hypoglycemia in non-diabetic models.
Structural Modifications and Extended Half-Life
Native GLP-1 is rapidly degraded by DPP-4 and cleared by the kidneys within minutes. Semaglutide's Aib8 substitution prevents DPP-4 cleavage, while its C18 fatty acid side chain allows the peptide to reversibly bind to circulating albumin. This albumin binding protects the peptide from renal clearance and enzymatic degradation, yielding its extended ~1-week half-life and enabling once-weekly dosing protocols.
Metabolic and Body Composition Effects
The profound caloric deficit induced by Semaglutide leads to significant reductions in total body weight, primarily driven by fat mass loss. However, research models consistently demonstrate that single GLP-1 agonists like Sema also produce concurrent loss of lean muscle mass alongside fat mass. This body composition shift is an important variable that researchers actively monitor and compare against dual or triple agonists, which may offer better lean mass preservation.
Why Researchers Choose Semaglutide Over Dual or Triple Agonists
Versus Tirzepatide (GLP-1/GIP Dual): Tirzepatide adds a second pathway (GIP) that improves insulin sensitivity and may moderate gastrointestinal side effects, producing greater total weight loss (~20-22% vs ~15-17%). However, Semaglutide has a longer track record of clinical validation, extensive cardiovascular outcome data (SUSTAIN-6 trial), and remains the foundational baseline against which all newer incretins are compared. Researchers often choose Sema when they need the most extensively characterized GLP-1 agonist available.
Versus Retatrutide (GLP-1/GIP/Glucagon Triple): Retatrutide adds a third pathway (glucagon) that actively increases energy expenditure and burns liver fat, potentially producing even greater weight loss (~24% at 48 weeks). However, Retatrutide is still investigational and carries a risk of transient increased heart rate. Semaglutide, by contrast, is FDA-approved with a fully established safety profile, extensive Phase 3 data, and proven cardiovascular benefits, making it the preferred choice for researchers prioritizing clinical validation and long-term safety data.
Versus Traditional Weight Loss Research Models: Older research compounds often target only one pathway with limited clinical validation. Semaglutide provides a single-pathway approach with the most robust clinical evidence base of any incretin, making it the gold standard for comparative metabolic research.
Primary Research Applications
- Obesity and body composition modeling (fat mass vs. lean mass changes)
- Type 2 Diabetes Mellitus (T2DM) and glycemic control research
- Cardiovascular outcome and risk marker studies (SUSTAIN-6 trial data)
- Gastric emptying and satiety signaling investigations
- Comparative incretin-pathway studies (single vs. dual vs. triple agonists)
- Lean mass preservation strategies during caloric deficit
- Long-term metabolic sustainability and weight regain modeling
Semaglutide vs. Tirzepatide vs. Retatrutide: Comparative Metabolic Analysis
Researchers frequently compare these three compounds to understand the trade-offs between mechanism complexity, efficacy, and tolerability across incretin-based metabolic protocols.
| Feature | Semaglutide (Sema) | Tirzepatide (Tirz) | Retatrutide (RT) |
|---|---|---|---|
| Receptor Targets | GLP-1 (Single) | GLP-1, GIP (Dual) | GLP-1, GIP, Glucagon (Triple) |
| Mechanism Complexity | Single-pathway (appetite suppression + insulin sensitization) | Dual-pathway (appetite suppression + insulin sensitization) | Multi-pathway (appetite suppression + increased energy expenditure) |
| Weight Loss Potential (Research Data) | High (~15-17% at 68 weeks in Phase 3) | Very High (~20-22% at 72 weeks in Phase 3) | Highest (~24% at 48 weeks in Phase 2) |
| Hepatic Fat Reduction | Mild to Moderate | Moderate | Strong (glucagon-mediated lipid oxidation) |
| Lean Mass Loss Risk | Higher (significant lean mass loss alongside fat) | Moderate (may better preserve lean mass) | Moderate (glucagon may support lean mass) |
| Common Minor Side Effects (Research Models) | Nausea, vomiting, GI distress, potential muscle mass loss | Nausea, diarrhea, generally well-tolerated | Nausea, transient increased heart rate, GI distress |
| Clinical Development Stage | FDA-approved (Ozempic, Wegovy) | FDA-approved (Mounjaro, Zepbound) | Phase 3 trials ongoing |
| Research Status | Approved for medical use | Approved for medical use | Investigational (not approved for human use) |
Note: Clinical data for Semaglutide is from completed Phase 3 trials (STEP and SUSTAIN programs). Results may vary based on dosage (e.g., Sema5 vs Sema20 protocols), duration, and individual metabolic factors. Semaglutide is available in both approved pharmaceutical formulations and research-grade lyophilized powder.
Product Specifications
Chemical Specifications
| Specification | Value |
|---|---|
| Peptide Sequence | 31 Amino Acids (Modified GLP-1 Analog with C18 Fatty Acid) |
| CAS Number | 910463-68-2 |
| Synonyms | Semaglutide, Sema, Ozempic, Wegovy, GLP-1 Analog |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molar Mass | ~4113.6 g/mol |
| Peptide Length | 31 amino acids |
| Purity | ≥99% by HPLC |
| Form | Lyophilized white powder |
Note: Formulation ratios and purity metrics may vary by batch. Always refer to the batch-specific Certificate of Analysis (COA) included with your order for exact composition and laboratory-verified specifications.
Storage and Stability
| Condition | Recommendation |
|---|---|
| Long-term storage (lyophilized) | −20°C in tightly sealed container, protected from light and moisture – stable for up to 24 months |
| Shipping | Room temperature (15–25°C) for short periods (up to two weeks) – no significant degradation |
| After reconstitution | Refrigerate at 2–8°C; use within 28 days |
| Handling precautions | Avoid repeated freeze-thaw cycles and vigorous shaking to maintain peptide integrity |
Research Protocol Considerations
Semaglutide is typically reconstituted with bacteriostatic water. Like Retatrutide and Tirzepatide, Semaglutide protocols utilize milligram (mg) quantities. Because it is administered in milligram amounts (ranging from lower 0.25mg-0.5mg protocols to higher 1mg-2.4mg protocols reported in advanced trials), researchers typically use reconstitution volumes of 1–3 mL to allow for precise measurement with standard insulin syringes. Clinical trials utilize weekly subcutaneous administration with gradual dose escalation (typically in 0.25mg-0.5mg increments) to assess gastrointestinal tolerance.
Investigators studying comprehensive metabolic protocols often research Semaglutide alongside other metabolic compounds such as Tirzepatide (for comparative dual-agonist studies), Retatrutide (for triple-agonist comparisons), or compounds aimed at preserving lean mass during caloric deficits, depending on the specific metabolic endpoints being evaluated.
Dose Escalation Protocols Reported in Clinical Trials
In published clinical trial literature (STEP program), Semaglutide dosing typically follows a gradual escalation schedule. Starting doses of 0.25mg weekly for four weeks are reported, escalating to 0.5mg for weeks five through eight, then 1.0mg for weeks nine through twelve, reaching maintenance doses of 1.7mg or 2.4mg weekly. This stepwise approach is designed to assess gastrointestinal tolerance and evaluate dose-dependent metabolic endpoints. These schedules are derived from published data and provided for protocol design reference only.
Semaglutide Research FAQ
Q: Is Semaglutide approved for human use in research quantities?
A: Research-grade Semaglutide is distinct from FDA-approved pharmaceutical formulations such as Ozempic and Wegovy. While Semaglutide as an active pharmaceutical ingredient has received FDA approval for type 2 diabetes (Ozempic) and obesity (Wegovy), research-grade Semaglutide is supplied as a lyophilized powder for laboratory research purposes only. It is not approved for human or veterinary consumption in this form and is not a substitute for any FDA-approved medication. Researchers should consult all applicable institutional and regulatory guidelines before initiating study protocols.
Q: What are the body composition effects of Semaglutide in research models?
A: Yes, this is a well-documented observation in clinical trials. The profound caloric deficit induced by Semaglutide leads to significant weight loss, but research consistently shows that a portion of this weight loss comes from lean muscle mass, not just fat. This body composition shift is an important variable that researchers actively monitor. Newer dual and triple agonists (like Tirzepatide and Retatrutide) may offer better lean mass preservation, though this is an area of ongoing investigation.
Q: What is the primary difference between Semaglutide and Tirzepatide?
A: Semaglutide is a single GLP-1 receptor agonist, while Tirzepatide is a dual GLP-1/GIP receptor agonist. The addition of GIP receptor agonism in Tirzepatide has been shown to produce superior weight loss (~20-22% vs ~15-17%), improved glycemic control, and enhanced gastrointestinal tolerability compared to GLP-1-only compounds. GIP appears to moderate the nausea commonly associated with GLP-1 receptor activation. Researchers choose Semaglutide when a single-pathway baseline comparator is needed.
Q: Can Semaglutide be stacked with Tirzepatide or Retatrutide in research protocols?
A: Generally, no. Because Semaglutide strongly activates the GLP-1 receptor, adding Tirzepatide (which also activates GLP-1 and GIP) or Retatrutide (which activates GLP-1, GIP, and glucagon) would be redundant and would significantly increase the risk of severe gastrointestinal side effects without providing proportional benefits. Researchers typically study them as comparative alternatives rather than stacking them together.
Q: How does Semaglutide dosing escalate in research protocols?
A: In published clinical trial literature from the STEP program, Semaglutide dosing typically follows a gradual escalation schedule to assess gastrointestinal tolerance. Starting doses of 0.25mg weekly are reported for the first four weeks, escalating to 0.5mg for weeks five through eight, then 1.0mg for weeks nine through twelve, reaching maintenance doses of 1.7mg or 2.4mg weekly thereafter. This stepwise approach is designed to evaluate dose-dependent metabolic endpoints. These schedules are derived from published clinical trial data and are provided for protocol design reference only.
Q: What is the primary difference between Semaglutide, Tirzepatide, and Retatrutide?
A: These three compounds represent successive generations of incretin-based metabolic research. Semaglutide is a single GLP-1 receptor agonist primarily targeting appetite suppression and glycemic control. Tirzepatide is a dual GLP-1/GIP agonist adding insulin sensitization with potentially better gastrointestinal tolerability. Retatrutide is a triple GLP-1/GIP/glucagon agonist that adds direct thermogenic effects, potentially increasing energy expenditure. Semaglutide has the longest track record of clinical validation and cardiovascular outcome data, making it the foundational baseline in comparative metabolic research.
Scientific References and Citations
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
- Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619
- Wilding JPH, Lingvay I, Deanfield JE, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963